Patterns of loss of heterozygosity in breast carcinoma during neoadjuvant chemotherapy

International Journal of Oncology

Volumn 30, Issue 5, 2007, Pages 1145-1151

  Oudin, Claire ^a   Bonnetain, Frank ^a   Boidot, Romain ^a   Végran, Frédérique ^a   Soubeyrand, Marie Sophie ^a   Arnould, Laurent ^a   Riedinger, Jean Marc ^a   Lizard Nacol, Sarab ^a  

^a CENTRE GEORGES FRANÇOIS LECLERC   (France)

Author keywords

Breast cancer; Double strand breaks; Loss of heterozygosity; Neoadjuvant chemotherapy

Indexed keywords

DNA; MICROSATELLITE DNA;

ADJUVANT CHEMOTHERAPY; ARTICLE; BIOPSY; BREAST TUMOR; CHEMISTRY; CHROMOSOME; CHROMOSOME MAP; DNA DAMAGE; DNA REPAIR; DRUG EFFECT; FEMALE; GENE EXPRESSION PROFILING; GENETICS; HETEROZYGOSITY LOSS; HUMAN; METHODOLOGY; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE;

BASE SEQUENCE; BIOPSY; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CHROMOSOME MAPPING; CHROMOSOMES; DNA; DNA DAMAGE; DNA REPAIR; FEMALE; GENE EXPRESSION PROFILING; HUMANS; LOSS OF HETEROZYGOSITY; MICROSATELLITE REPEATS; MOLECULAR SEQUENCE DATA;

EID: 34447311975     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.30.5.1145     Document Type: Article

References (36)

1. Fink D, Nebel S, Norris PS, Aebi S, Kim HK and Howell SB: The effect of different chemotherapeutic agents on the enrichment of DNA mismatch repair-deficient tumour cells. Br J Cancer 77: 703-708, 1998.
2. Picard SF, Franco N, Sergent C, Chauffert B and Lizard-Nacol S: Analysis of microsatellite instability in acquired-drug resistance human tumor cell lines. Oncol Rep 9: 971-976, 2002.
3. Watanabe T, Wu TT, Catalano PJ, Ueki T, Satriano R, Haller DG, Benson AB and Hamilton SR: Molecular predictors of survival after adjuvant chemotherapy for colon cancer. N Engl J Med 344: 1196-1206, 2001.
4. Elsaleh H, Powell B, McCaul K, Grieu F, Grant R, Joseph D and Iacopetta B: P53 alteration and microsatellite instability have predictive value for survival benefit from chemotherapy in stage III colorectal carcinoma. Clin Cancer Res 7: 1343-1349, 2001.
5. Ribic MC, Sargent DJ, Moore MJ, Thibodeau SN, French AJ, Goldberg RM, Hamilton SR, Laurent-Puig P, Gryfe R, Shepherd LE, Tu D, Redston M and Gallinger S: Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 349: 247-257, 2003.
6. Benatti P, Gafà R, Barana D, Marino M, Scarselli A, Pedroni M, Maestri I, Guerzoni L, Roncucci L, Menigatti M, Roncari B, Maffei S, Rossi G, Ponti G, Santini A, Losi L, Di Gregorio C, Oliani C, De Leon MP and Lanza G: Microsatellite instability and colorectal cancer prognosis. Clin Cancer Res 11: 8332-8340, 2005.
7. Blons H, Cabelguenne A, Carnot F, Laccourreye O, De Waziers I, Hamelin R, Brasnu D, Beaune P and Laurent-Puig P: Microsatellite analysis and response to chemotherapy in head-and-neck squamous-cell carcinoma. Int J Cancer 84: 410-415, 1999.
8. Barratt PL, Seymour MT, Stenning SP, Georgiades I, Walker C, Birbeck K and Quirke P: Adjuvant X-ray and fluorouracil infusion study. DNA markers predicting benefit from adjuvant fluorouracil in patients with colon cancer: a molecular study. Lancet 360: 1381-1391, 2002.
9. Taback B, O'Day SJ, Boasberg PD, Shu S, Fournier P, Elashoff R, Wang HJ and Hoon DS: Circulating DNA microsatellites: molecular determinants of response to biochemotherapy in patients with metastatic melanoma. J Natl Cancer Inst 96: 152-156, 2004.
10. El-Naggar AK, Papadimitrakopoulou V, Shin DM, Shin HC, Fan Y, Zhou X, Clayman G, Lee JJ, Lee JS, Hittelman WN, Lippman SM and Hong WK: Phenotype and genotype of advanced premalignant head and neck lesions after chemopreventive therapy. J Natl Cancer Inst 90: 1545-1551, 1998.
11. Grundei T, Vogelsang H, Ott K, Mueller J, Scholz M, Becker K, Fink U, Siewert JR, Hofler H and Keller G: Loss of heterozygosity and microsatellite instability as predictive markers for neoadjuvant treatment in gastric carcinoma. Clin Cancer Res 6: 4782-4788, 2000.
12. Ott K, Vogelsang H, Muellr J, Becker K, Muller M, Fink U, Siewert JR, Hofler H and Keller G: Chromosomal instability rather than p53 mutation is associated with response to neoadjuvant cisplatin-based chemotherapy in gastric carcinoma. Clin Cancer Res 9: 2307-2315, 2003. (Pubitemid 36687657)
13. Moynahan ME and Jasin M: Loss of heterozygosity induced by a chromosomal double-strand break. Proc Natl Acad Sci USA 94: 8988-8993, 1997.
14. Pfeiffer P, Goedecke W and Obe G: Mechanisms of DNA double-strand break repair and their potential to induce chromosomal aberrations. Mutagenesis 15: 289-302, 2000. (Pubitemid 30612188)
15. Hoeijmakers JHJ: Genome maintenance mechanisms for preventing cancer. Nature 411: 366-374, 2001.
16. Maitra A, Wistuba II, Washington C, Virmani AK, Ashfaq R, Milchgrub S, Gazdar AF and Minna JD: High-resolution chromosome 3p allelotyping of breast carcinomas and precursor lesions demonstrates frequent loss of heterozygosity and a discontinuous pattern of allele loss. Am J Pathol 159: 119-130, 2001. (Pubitemid 33704198)
17. Wang ZM, Chen ZP, Xu ZY, Christodoulopous G, Bello V, Mohr G, Aloyz R and Panasci LC: In vitro evidence for homologous recombination repair in resistance to Melphalan. J Natl Cancer Inst 93: 1473-1478, 2001.
18. Hu B, Wang H, Wang X, Lu H-R, Huang C, Powell SN, Huebner K and Wang Y: Fhit and CHK1 have opposing effects on homologous recombination repair. Cancer Res 65: 8613-8616, 2006. (Pubitemid 41377345)
19. Kennedy RD and D'Andrea A: DNA repair pathways in clinical practice: lessons from pediatric cancer susceptibility syndromes. J Clin Oncol 4: 3799-3808, 2006.
20. Anderson RD and Berger NA: Mutagenecity and carcinogenicity of topoisomerase-interactive agents. Mutat Res 309: 109-142, 1994.
21. Froelich JJ, Schneller FR and Zahn RK: The influence of radiation and chemotherapy-related DNA strand breaks on carcinogenesis: an evaluation. Clin Chem Lab Med 37: 403-408, 1999.
22. Fojo T: Cancer, DNA repair mechanisms, and resistance to chemotherapy. J Natl Cancer Inst 93: 1434-1436, 2001.
23. Sataloff DM, Mason BA, Prestipino AJ, Seinige UL, Lieber CP and Baloch Z: Pathologic response to induction chemotherapy in locally advanced carcinoma of the breast: a determinant of outcome. J Am Coll Surg 180: 297-306, 1995.
24. Franco N, Arnould L, Mége F, Picard SF, Arveux P and Lizard-Nacol S: Comparative analysis of molecular alterations in fibroadenomas associated or not with breast cancer. Arch Surg 138: 289-295, 2003.
25. Shen CY, Yu JC, Lo YL, Kuo CH, Yue CT, Jou YS, Huang CS, Lung JC and Wu CW: Genome-wide search for loss of heterozygosity using laser capture microdissected tissue of breast carcinoma: an implication for mutator phenotype and breast cancer pathogenesis. Cancer Res 60: 3884-3892, 2000.
26. Khanna KK and Jackson SP: DNA double-strand breaks: signaling, repair and the cancer connection. Nat Genet 27: 247-254, 2001.
27. Patel U, Grundfest-Broniatowski S, Gupta M and Banerjee S: Microsatellite instabilities at five chromosomes in primary breast tumors. Oncogene 9: 3695-3700, 1994.
28. Dillon EK, De Boer WB, Papadimitriou JM and Turbett GR: Microsatellite instability and loss of heterozygosity in mammary carcinoma and its probable precursors. Br J Cancer 76: 156-162, 1997.
29. Kasami M, Vnencak-Jones CL, Manning S, Dupont WD and Page DL: Loss of heterozygosity and microsatellite instability in breast hyperplasia. No obligate correlation of these genetic alterations with subsequent malignancy. Am J Pathol 150: 1925-1932, 1997.
30. Kerangueven F, Noguchi T, Coulier F, Allione F, Wargniez V, Simony-Lafontaine J, Longy M, Jacquemier J, Sobol H, Eisinger F and Birnbaum D: Genome-wide search for loss of heterozygosity shows extensive genetic diversity of human breast carcinomas. Cancer Res 57: 5469-5474, 1997.
31. Boland R, Thibodeau SN, Hamilton SR, Idransky D, Eshleman JR, Burt RW, Meltzer SJ, Ridriguez-Bigas M, Fodde R, Ranzani GN and Srivastava S: A national cancer institute workshop on microsatellite instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res 58: 5248-5257, 1998.
32. Thiagalingam S, Foy RL, Cheng KH, Lee HJ, Thiagalingam A and Ponte JF: Loss of heterozygosity as a predictor to map tumor suppressor genes in cancer: molecular basis of its occurrence. Curr Opin Oncol 14: 65-72, 2002.
33. Dronkert MG and Kanaar R: Repair of DNA interstrand crosslinks. Mutat Res 486: 217-247, 2001.
34. Inoue H, Ishii H, Alder H, Snyder E, Druck T, Heubner K and Croce CM: Sequence of the FRA3B common fragile region: implications for the mechanism of FHIT deletion. Proc Natl Acad Sci USA 94: 14584-14589, 1997. (Pubitemid 28041417)
35. Smith DI, Huang H and Wang L: Common fragile sites and cancer. Int J Oncol 12: 187-196, 1998.
36. Schwartz M, Zlotorynski E, Goldberg M, Ozeri E, Rahat A, Le Sage C, Chen BPC, Chen DJ, Agami R and Kerem B: Homologous recombination and non-homologous end-joining repair pathways regulate fragile site stability. Genes Dev 19: 2715-2726, 2006.